Evidence map›Paper›PMID 40804302›Full record

ArticleCommunications biology2025

So close yet so far apart: distinct flanking sequence recognition by DNMT3A and DNMT3B.

Ayşe Berçin Barlas, Ezgi Karaca

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ayşe Berçin BarlasOmics and Computational Biology Program, Izmir Biomedicine and Genome Center, Izmir, Türkiye.ORCID http://orcid.org/0000-0003-3100-9553
Ezgi KaracaOmics and Computational Biology Program, Izmir Biomedicine and Genome Center, Izmir, Türkiye. ezgi.karaca@ibg.edu.tr.ORCID http://orcid.org/0000-0002-4926-7991

Funding

European Molecular Biology Organization (EMBO) IG 4421
6 · The paper itself

Abstract

DNMT3A and DNMT3B are closely related DNA methyltransferases that catalyze de novo CpG methylation and have distinct preferences for flanking sequences. Despite sharing 91% sequence similarity within their catalytic domains, these paralogs show non-overlapping genomic targeting and divergent biological roles. To uncover the mechanistic basis of this specificity, we performed 16µs of all-atom molecular dynamics simulations on DNMT3A and DNMT3B complexes bound to CpG substrates with varied +2 flanking bases (i.e., CGX). To resolve their base- and shape-readout mechanisms at atomistic detail, we introduced a Comparative Dynamics Analysis (CDA) framework. Our CDA approach revealed that DNMT3A relies on a rigid, sequence-specific hydrogen bonding network and shape-constrained electrostatic anchoring, whereas DNMT3B employs a more flexible and distributed interface, allowing broader substrate tolerance. This represents the first systematic analysis of shape readout in DNMT3 enzymes and demonstrates how flanking sequence specificity is dynamically encoded by two nearly identical proteins. Our findings not only clarify how closely related DNA-modifying enzymes diverge in recognition strategies, but also lay the foundation for future efforts to engineer paralog-specific protein-DNA interactions.

Indexed as

DNA (Cytosine-5-)-MethyltransferasesCpG IslandsDNADNA MethylationDNA Methyltransferase 3ADNA Methyltransferase 3BHumansMolecular Dynamics SimulationProtein BindingSubstrate SpecificityDNADNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNA Methyltransferase 3BDNMT3A protein, human

Identifiers

PMID40804302
PMCPMC12350793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.